Assyro AI

FDA Orange Book · active-ingredient family

Terbinafine hydrochloride

Terbinafine hydrochloride is approved as 6 brand and 16 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:LAMISIL · NDA 022071

6

Brand (NDA)

16

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · cream, granule, solution, spray, tablet

ProductApplicantApplicationTEApproved
LAMISILRLD×2NOVARTISNDA 022071Sep 28, 2007
LAMISIL ATRLD×2KARO HLTHCARENDA 021124Mar 17, 2000
LAMISILRLDKARO HLTHCARENDA 020980Mar 09, 1999
LAMISILRLDNOVARTISNDA 020539May 10, 1996
LAMISILKARO HLTHCARENDA 020749Oct 17, 1997
LAMISILNOVARTISNDA 020192Dec 30, 1992

Generic (ANDA) products (16)

ProductApplicantApplicationTEApproved
TERBINAFINE HYDROCHLORIDEBRECKENRIDGE PHARMANDA 077714Jun 04, 2010
TERBINAFINE HYDROCHLORIDESUN PHARMA CANADAANDA 077511Jul 02, 2007
TERBINAFINE HYDROCHLORIDEAUROBINDO PHARMAANDA 078297ABJul 02, 2007
TERBINAFINE HYDROCHLORIDECHARTWELLANDA 078199ABJul 02, 2007
TERBINAFINE HYDROCHLORIDECIPLAANDA 077137ABJul 02, 2007
TERBINAFINE HYDROCHLORIDEEMED MEDCLANDA 077919ABJul 02, 2007
TERBINAFINE HYDROCHLORIDEGEDEON RICHTER USAANDA 077065Jul 02, 2007
TERBINAFINE HYDROCHLORIDEGLENMARK PHARMS LTDANDA 078157ABJul 02, 2007
TERBINAFINE HYDROCHLORIDEHERITAGE PHARMA AVETANDA 076377Jul 02, 2007
TERBINAFINE HYDROCHLORIDEINVAGEN PHARMSANDA 077533ABJul 02, 2007
TERBINAFINE HYDROCHLORIDEMYLANANDA 077136Jul 02, 2007
TERBINAFINE HYDROCHLORIDENATCO PHARMAANDA 077195Jul 02, 2007
TERBINAFINE HYDROCHLORIDEORBION PHARMSANDA 078163ABJul 02, 2007
TERBINAFINE HYDROCHLORIDEROXANEANDA 077223Jul 02, 2007
TERBINAFINE HYDROCHLORIDESENORES PHARMSANDA 076390ABJul 02, 2007
TERBINAFINE HYDROCHLORIDEWOCKHARDTANDA 078229Jul 02, 2007

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Terbinafine hydrochloride — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.